Vcanbio Cell & Gene Engineering Corp., Ltd Share Price

Equities

600645

CNE000000545

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 03:30:00 26/04/2024 am IST 5-day change 1st Jan Change
16.45 CNY +0.73% Intraday chart for Vcanbio Cell & Gene Engineering Corp., Ltd +6.68% -18.85%

Financials

Sales 2022 1.55B 215M 17.89B Sales 2023 1.59B 219M 18.29B Capitalization 9.49B 1.31B 109B
Net income 2022 113M 15.6M 1.3B Net income 2023 106M 14.63M 1.22B EV / Sales 2022 4.31 x
Net cash position 2022 1.25B 173M 14.41B Net cash position 2023 1.47B 202M 16.86B EV / Sales 2023 5.04 x
P/E ratio 2022
70.9 x
P/E ratio 2023
88.1 x
Employees 2,332
Yield 2022 *
-
Yield 2023
-
Free-Float 71.64%
More Fundamentals * Assessed data
Dynamic Chart
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024. CI
Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback announced on February 19, 2024, has closed with 6,181,212 shares, representing 1.32% for CLP 100 million. CI
Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024. CI
Vcanbio Cell & Gene Engineering Corp., Ltd announces an Equity Buyback for CLP 200 million worth of its shares. CI
Vcanbio Cell & Gene Engineering Corp., Ltd authorizes a Buyback Plan CI
Shanghai Vcanbio Jisheng Cell Technology Co., Ltd. announced that it has received CNY 20 million in funding from Vcanbio Cell & Gene Engineering Corp., Ltd CI
Shanghai Vcanbio Jisheng Cell Technology Co., Ltd. announced that it expects to receive CNY 20 million in funding from Vcanbio Cell & Gene Engineering Corp., Ltd CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Vcanbio Cell & Gene Gets Greenlight to Trial COVID-19 Drug MT
Vcanbio Cell & Gene Engineering Corp., Ltd agreed to acquire additional 3% stake in Heyuan Biological Technology Co., Ltd. from Beijing Fuyuan Zhiyuan Biotechnology Partnership (Limited Partnership). CI
Vcanbio Cell & Gene Engineering Corp., Ltd(XSSC:600645) added to S&P Global BMI Index CI
MET Group signs energy supply deal with Commonwealth LNG RE
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
More news
1 day+0.73%
1 week+6.68%
Current month+0.30%
1 month+2.49%
3 months-5.24%
6 months-12.45%
Current year-18.85%
More quotes
1 week
15.22
Extreme 15.22
16.50
1 month
15.05
Extreme 15.05
16.65
Current year
12.88
Extreme 12.88
20.35
1 year
12.88
Extreme 12.88
21.77
3 years
12.88
Extreme 12.88
28.67
5 years
12.88
Extreme 12.88
34.77
10 years
12.88
Extreme 12.88
79.58
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 30/09/30
Director of Finance/CFO 42 25/22/25
Director/Board Member 53 01/16/01
Members of the board TitleAgeSince
Chief Executive Officer 57 30/09/30
Director/Board Member 64 19/20/19
Director/Board Member 59 16/23/16
More insiders
Date Price Change Volume
26/24/26 16.45 +0.73% 4,613,369
25/24/25 16.33 +1.24% 4,311,099
24/24/24 16.13 +1.38% 3,420,213
23/24/23 15.91 +1.73% 3,544,628
22/24/22 15.64 +1.43% 4,008,999

End-of-day quote Shanghai S.E., April 26, 2024

More quotes
VCANBIO CELL & GENE ENGINEERING CORP., LTD is a China-based company, principally engaged in the preparation, detection and storage of cells. The Company is also engaged in cell culture and gene detection and storage, as well as the production and sale of cytokines culture solutions, cosmetics and detection reagents. The Company conducts its businesses mainly within domestic markets.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 600645 Stock